Background {#Sec1}
==========

Primary retroperitoneal mucinous cystadenocarcinoma (PRMC) is extremely rare, with the first case was reported in 1965 \[[@CR1]\]. Since then, only 61 cases have been reported in the English literature, to our knowledge. Little is known about the biological behavior and pathogenesis of this disease. The diagnosis is often confusing preoperatively. In addition, the optimum treatments and prognosis of PRMCs remain to be uncertain. We herein report a case of PRMC with 80 months of follow-up.

Case presentation {#Sec2}
=================

A 29-year-old woman was admitted to our hospital for further examination due to abdominal pain and a cystic mass in the right lower abdomen. A physical examination revealed no tumor in her abdomen on palpation. Contrast-enhanced computed tomography (CT) revealed a cystic and well-defined tumor of 8.5 cm in diameter behind the ascending colon. The tumor had enhanced and segmented components (Fig. [1](#Fig1){ref-type="fig"}). Magnetic resonance imaging (MRI) demonstrated a mass behind the ascending colon of iso-intensity on T1-weighted and high intensity on T2-weighted images. Other bi-cystic masses of 8 cm in diameter at the right ovary and uterine fibroids were also observed (Fig. [2](#Fig2){ref-type="fig"}). There was no evidence of invasion to adjacent tissues or distant metastasis. Based on imaging findings, the differential diagnosis of this tumor was thought to be neurogenic tumor, leiomyosarcoma, malignant fibrous histiocytoma, and primary retroperitoneal tumor. The serum levels of carcinoembryonic antigen (CEA) were within normal limits, while those of cancer antigen (CA) 19-9 and 125 (CA125) were elevated. She was diagnosed with unknown retroperitoneal tumor with benign right ovarian cyst and uterine fibroids.Fig. 1(**a**) Horizontal and (**b**) sagittal image of CT reveals a cystic and well-defined tumor 8.5 cm in diameter behind the ascending colon (arrow heads) with enhanced and segmented components (arrow) Fig. 2MRI demonstrates a cystic mass of iso-intensity on T1-weighted and high intensity on T2-weighted images (arrow heads), uterine fibroids (arrow), and cystic masses at the right ovary (broken arrow)

Laparotomy was performed, revealing a tumor capsulated with a thin wall behind the ascending colon, an ovarian cyst, and uterine fibroids. The tumor was completely removed without injury of its capsule. The ovarian cyst was enucleated, but the uterine fibroids were not removed in accordance with the preoperative informed consent.

A histopathological examination showed that the tumor was unilocular with a large mural solid nodule. In the nodule, there were multi-cystic lesions covered with papillovillous hyperchromatic cells made of intestinal type epithelium ranging from adenoma- to invasive adenocarcinoma type. In addition, ovarian-like stroma was seen in the cyst wall, but ovarian tissue and teratomatous elements were not (Fig. [3](#Fig3){ref-type="fig"}). An immuno-histopathological examination revealed positivity for CK 7 and CEA but negativity for CK 20 in the tumor cells (Fig. [4](#Fig4){ref-type="fig"}), and negativity for estrogen and progesterone receptors in the ovarian-like stromal cells. Considering the histopathological features and the location, the tumor was diagnosed as PRMC without sarcomatous change.Fig. 3Gross appearance of the specimen (**a**). Microscopic images show that the tumor consists of a unilocular cyst and a large mural solid nodule (**b**). In the nodule, multi-cystic lesions covered by papillovillous hyperchromatic cells are observed. They comprise intestinal-type epithelium with goblet cells (**c**). Some of them are invasive adenocarcinoma cells (**d**) with stromal invasion (**e**). Ovarian-like stroma is also observed (**f**) Fig. 4An immuno-histopathological examination revealed positivity for CK 7 (**a**) and CEA (**b**) but negativity for CK 20 in the tumor cells

The surgical margin was free from tumor cells. The right ovarian cyst was diagnosed as an endometrial cyst (chocolate cyst). After the surgery, she had no major complications and left our hospital 8 days later. During the follow-up period of 80 months, neither local recurrence nor distant metastasis was found. Her other ovarian cysts, however, gradually enlarged, so she underwent surgery to remove them 4 years after the initial surgery. A histopathological examination revealed that they were benign chocolate cysts. The serum levels of CA 125 and CA 19-9, which had been elevated before the second surgery, normalized after surgery.

Discussion {#Sec3}
----------

Retroperitoneal mucinous cystic neoplasms, including cystadenoma and cystadenocarcinoma, are so rare that the accurate incidence is not available. We searched the PubMed database for published English studies using the terms "primary" and "retroperitoneal" and "mucinous" and "cystadenocarcinoma" or "adenocarcinoma." Cases of adenomas, borderline tumors, and metastasis to the retroperitoneum were excluded, but mixed-type tumors were included. Our present case is only the 62nd case (Table [1](#Tab1){ref-type="table"}) \[[@CR1]--[@CR46]\]. The mean age is 44.7 years (range 18--86 years), and the mean tumor size is 13.6 cm (range 3 to 26 cm). Only five cases were reported in males. To our knowledge, among the 51 cases in which the follow-up period was mentioned (range 1--130 months; median 16 months), only 7 cases had been followed for over 5 years. They are all alive without recurrence of disease. Although most PRMCs tend not to develop further disease, some with sarcoma-like or anaplastic components have a very aggressive character and can metastasize. Myriokefalitaki \[[@CR9]\] reported that the 5-year overall survival was 75.4%.Table 1Published English studies searched in PubMedCase no.AuthorSexAgeDiameter(cm)Adjuvant chemotherapyFollow-up (month)Status1Douglas 1965 \[[@CR1]\]F185NoN/RDOD2Tykkä 1975 \[[@CR2]\]F2310No11DOD3Roth 1977 \[[@CR3]\]F48N/RNo6DOD4Fujii 1986 \[[@CR4]\]F6923No36NED5Nelson 1988 \[[@CR5]\]F3520No22NED6Chida 1990 \[[@CR6]\]F42N/RNoN/RN/R7Seki 1990 \[[@CR7]\]F4211NoN/RN/R8Park 1990 \[[@CR8]\]F4024Yes3NED9Jorgensen 1991 \[[@CR9]\]F388No9NED10Søndergaard 1991 \[[@CR10]\]F3713No18NED11Gotoh 1992 \[[@CR11]\]F4412.5Yes4DOD12Tenti 1994 \[[@CR12]\]F4620Yes33NED13F4520No19NED14Motoyama 1994 \[[@CR13]\]F4211N/RN/RN/R15Carabias 1995 \[[@CR14]\]F4315No24NED16Lee 1996 \[[@CR15]\]F5520No30NED17F4517No15NED18Dore 1996 \[[@CR16]\]F4520No16NED19Uematsu 2000 \[[@CR17]\]F8623No72NED20Suzuki 2001 \[[@CR18]\]F4015No15NED21Tangjitgamol 2002 \[[@CR19]\]F4112Yes18NED22Kessler 2002 \[[@CR20]\]F3811.5N/R60NED23Mikami 2003 \[[@CR21]\]F3816Yes18DOD24Song 2005 \[[@CR22]\]F7212No4DOD25Sonntag 2005 \[[@CR23]\]F605No12NED26Thamboo 2006 \[[@CR24]\]M6424No18NED27Fan 2006 \[[@CR25]\]F6817NoN/RN/R28Law 2006 \[[@CR26]\]F3511No60NED29de Leon 2007 \[[@CR27]\]F3619Yes8AWD30F2126No6NED31Kashima 2007 \[[@CR28]\]F2817No13NED32Lee 2007 \[[@CR29]\]F3215Yes42NED33Green 2007 \[[@CR30]\]M8326No6NED34Tjalma 2007 \[[@CR31]\]F743Yes31DOD35Moral 2008 \[[@CR32]\]F4724No8NED36Youssef 2008 \[[@CR33]\]F7010Yes24NED37Roma 2009 \[[@CR34]\]F3513No13NED38F4721No1NED39F2418No2NED40F4310No5DOD41F4011No9DOD42F278No11NED43F637.5No14AWD44F3118No26AWD45F4826No58AWD46F4015No58NED47F35N/RNo91NED48F4911No130NED49F20N/RNoN/RN/R50Hrora 2009 \[[@CR35]\]M425No6NED51Dierickx 2010 \[[@CR36]\]F5013Yes58NED52Jian 2011 \[[@CR37]\]F2114.6Yes6AWD53Kanayama 2012 \[[@CR38]\]F4025No6AWD54Feng 2013 \[[@CR39]\]M634No13NED55Hanhan 2014 \[[@CR40]\]F3722NoN/RN/R56Shiau 2013 \[[@CR41]\]M597.5No79NED57Kurita 2014 \[[@CR42]\]F3019No32AWD58Kamiyama 2015 \[[@CR43]\]F6210No15DOD59Cupp 2015 \[[@CR44]\]F3920YesN/RN/R60Dong 2014 \[[@CR45]\]F523.8NoN/RN/R61Myriokefalitaki 2016 \[[@CR46]\]F5624No17NED62Present caseF288.5No80NED*N/R* not recorded, *DOD* dead of disease, *NED* no evidence of disease, *AWD* alive with disease

The etiology and biological behavior of PRMCs are still unclear; however, some hypotheses have been proposed to explain the genesis of these tumors as follows: (1) heterotopic ovarian tissue \[[@CR3], [@CR11], [@CR47]\], (2) monodermal variant of teratomas \[[@CR22], [@CR48]\], (3) intestinal duplication \[[@CR49]\], and (4) coelomic metaplasia \[[@CR4], [@CR8], [@CR12], [@CR50]\]. In our case, ovarian-like stroma was histopathologically found in the tumor, although no definitive evidence of ovarian tissue was observed, which was also supported by the results of an immunohistochemical examination of the estrogen and progesterone receptors. These findings exclude the hypothesis of heterotopic ovarian tissue. In addition, the hypotheses of teratoma and intestinal duplication can also be excluded because of the lack of structures of teratoma or well-developed intestinal mucosa and smooth muscle. The fourth hypothesis, which is most well-described in the previous literature, is that PMRCs occur from invaginations of the peritoneal epithelium during embryogenesis. Those invaginated coelomic epithelial cells form cysts that may act like epithelial ovarian tissue and undergo the process of Müllerian differentiation. Eventually, the coelomic epithelia of these cysts undergo metaplasia and develop a spectrum of histological cells in different stages. In our case, the ovarian-like stroma and intestinal type epithelium ranged from adenoma-type mucinous cells to invasive adenocarcinoma cells, which may be explained by the last theory. In addition, the pattern of immunohistochemical expression of CK 7 and CK 20 is similar to those seen in ovarian and pancreatic mucinous neoplasms.

There are no pathognomonic clinical or radiological findings for PRMC, making the preoperative diagnosis of this disease challenging. PRMCs usually present as a multi- or unilocular cystic mass, varying in size and localized anywhere in the retroperitoneal space. Regarding the imaging findings, the diagnostic value of computed tomography and MRI is similar, but MRI can further characterize these lesions and identify their mucinous component. Notable radiographic findings may include thickening and calcification of the cyst wall or mural nodules on imaging that may suggest malignant lesions \[[@CR27]\]. Aspiration cytology and/or a biopsy may help with the diagnosis, although they carry risks of recurrence and dissemination in cystic tumors. Serological investigations provide limited diagnostic utility. Tumor markers, including CEA, CA 125, and CA 19-9, are also not very helpful for differentiating from other benign tumors, including ovarian cyst, cystic lymphangioma, and cystic methothelioma. Indeed, in our case, the elevation of serum levels of CA19-9 and CA 125 was also observed during the follow-up period. However, these levels normalized after she underwent a second surgery to resect the benign ovarian cysts. Therefore, imaging examinations such as CT or ultrasonography are the most effective tools for performing follow-up for PRMC.

The management of PRMC is not well established. There is currently no significant chemotherapy for PRMC. The commonly used chemotherapeutic regimes were cyclophosmide and adriamycin, cyclophosmide, adriamycin and cisplatin, cisplatin alone, carboplatin and paclitaxel, or carboplatin alone. Of the 12 patients who received adjuvant chemotherapy, 5 had recurrence (41.7%). Therefore, radical tumor excision is clearly mandatory. Radical resection without rupture is the standard therapy and the most important prognostic tool \[[@CR46]\], but whether lymphadenectomy or adjuvant chemotherapy provide benefit is still controversial \[[@CR11], [@CR12], [@CR19], [@CR21], [@CR27], [@CR29], [@CR31], [@CR36]\].

Conclusions {#Sec4}
===========

PRMC is a rare tumor that can have an aggressive potential for recurrence. The diagnosis remains difficult preoperatively, and surgeons should be aware of this disease as a differential diagnosis of large retroperitoneal cystic masses with indolent symptoms. The long-term management after surgery is not well established yet. Further studies about PRMC are needed to elucidate the etiology and effective treatments.
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